F/M Emerald Life Sciences Innovation ETF (LFSC)

Assets	$125.23M
Expense Ratio	0.54%
PE Ratio	35.68
Forward PE	24.55
Shares Out	2.79M
Dividend	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	1,598
Open	46.70
Previous Close	46.69
Day's Range	46.38 - 46.78
52-Week Low	32.84
52-Week High	48.78
Beta	0.96
Holdings	40
Inception Date	Oct 31, 2024

About LFSC

Fund Home Page

The F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care stocks. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.

• Asset Class: Equity
• Category: Health
• Region: North America
• Stock Exchange: Nasdaq
• Ticker Symbol: LFSC
• ETF Provider: F/m Investments

Top 10 Holdings

55.10% of assets

Name	Symbol	Weight
Replimune Group, Inc.	REPL	11.15%
LivaNova PLC	LIVN	7.41%
Cogent Biosciences, Inc.	COGT	5.75%
Travere Therapeutics, Inc.	TVTX	5.63%
BillionToOne, Inc.	BLLN	4.68%
Guardant Health, Inc.	GH	4.52%
Veradermics, Incorporated	MANE	4.24%
Spyre Therapeutics, Inc.	SYRE	4.16%
Corcept Therapeutics Incorporated	CORT	3.91%
United Therapeutics Corporation	UTHR	3.65%

Performance

LFSC had a total return of 37.85% in the past year, including dividends. Since the fund's inception, the average annual return has been 35.56%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP. Several fund data points are also provided by Finnhub.

Last checked:

Nov 11, 2026

Data Sources Report a data error